UNSPSC 51351519: Algestone acetonide

This classification denotes a therapeutic progestin with the molecular formula C24H34O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXD8I4Y1IH, chemically known as 16,17-((1-methylethylidene)bis(oxy))(16 deltaalpha)-pregn-4-ene-3,20-dione but more generally known as algestone acetonide, which bears US NIH Compound Identifier 21075. Most nations, for tariff and trade purposes, schedule algestone acetonide under HS 29372900. As of Q4 2014, ALGESTONE ACETONIDE remains US FDA's Preferred Term for this commodity.

Algestone acetonide bears US NLM identifiers UMLS ID C2983959 and NCI Concept Code C90967. SMILES: CC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(CC[C@H]4[C@H]3CCC5=CC(=O)CC[C@]45C)C)OC(O2)(C)C.

UNSPSC 51351519 Algestone acetonide is a Commodity code for a specific pharmaceutical active ingredient with limited recent state and local procurement activity. The code names a synthetic progestin used in hormone replacement and contraceptive formulations; state and local governments do not typically procure this ingredient directly, as pharmaceutical procurement at that level focuses on finished-form drugs dispensed through public health departments, Medicaid programs, correctional health services, and school-based clinics rather than raw pharmaceutical compounds. The issuing bodies that would acquire finished pharmaceutical products containing this or similar actives are state health departments, county public health agencies, state correctional systems, and school districts with nursing programs, but these entities source finished medications through group purchasing organizations, state Medicaid formularies, and federal supply schedules rather than through direct solicitations for individual active ingredients.

No recent state and local contract opportunities appear under this code in the available records. The code's scope — a single pharmaceutical active ingredient — does not align with typical state and local procurement patterns, which group pharmaceutical purchases by therapeutic class, finished-form drug product, or brand-generic equivalence rather than by active-ingredient UNSPSC taxonomy. Pursuit of this code is not recommended without evidence of an agency-specific solicitation for pharmaceutical raw materials or compounding inputs, which remains uncommon in state and local government purchasing.